US equities |
SPCX $167.02 ▲+5.07% NVDA $237.04 ▲+1.32% MU $1,063.87 ▼-1.03% TSLA $378.23 ▲+2.06% MSFT $526.46 ▲+1.73% SNDK $1,715.60 ▼-0.26% INTC $116.67 ▼-2.23% META $745.88 ▲+2.44%
FinancialContent

Medipharm Labs Corp (TSX:LABS)

0.0700 UNCHANGED
Delayed Quote Updated: 11:21 AM EDT, Oct 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Medipharm Labs Corp

< Previous 1 2 3 Next >
News headline image
MediPharm Labs Reports Positive Q2 2026 Net Income and Second Consecutive Quarter of Positive Adjusted EBITDA
From MediPharm Labs Corp.
Via GlobeNewswire
News headline image
MediPharm Labs Sets Date to Report Second Quarter 2026 Financial Results
From MediPharm Labs Corp.
Via GlobeNewswire
News headline image
MediPharm Labs Announces Positive Phase II LiBBY Trial Results Demonstrating Significant Reduction in Agitation Associated With Advanced Alzheimer’s Disease and Dementia
From MediPharm Labs Corp.
Via GlobeNewswire
News headline image
MediPharm Labs Announces Voting Results from the 2026 Annual and Special Meeting of Shareholders
From MediPharm Labs Corp.
Via GlobeNewswire
News headline image
MediPharm Labs Reminds Shareholders of Upcoming Annual and Special Meeting
From MediPharm Labs Corp.
Via GlobeNewswire
News headline image
MediPharm Labs Reports First Quarter 2026 Results Achieving Positive Adjusted EBITDA
From MediPharm Labs Corp.
Via GlobeNewswire
News headline image
MediPharm Labs Sets Date to Report First Quarter 2026 Financial Results
From MediPharm Labs Corp.
Via GlobeNewswire
News headline image
MediPharm Labs Positioned to Serve Growing U.S. Pharmaceutical and Clinical Research Demand Following Cannabis Rescheduling
From MediPharm Labs Corp.
Via GlobeNewswire
News headline image
MediPharm Labs Reports Full Year & Fourth Quarter 2025 Results with Over 40% Annual Growth in International Medical Revenue
From MediPharm Labs Corp.
Via GlobeNewswire
News headline image
MediPharm Labs Sets Date to Report Full Year and Fourth Quarter 2025 Financial Results
From MediPharm Labs Corp.
Via GlobeNewswire
News headline image
MediPharm Labs Announces CEO Transition: David Pidduck to Step Down; CFO Greg Hunter Appointed Interim CEO
From MediPharm Labs Corp.
Via GlobeNewswire
News headline image
MediPharm Labs to Enter New Market with Costa Rica Supply Agreement
From MediPharm Labs Corp.
Via GlobeNewswire
News headline image
Historic U.S. Cannabis Rescheduling Unlocks Potential Growth Opportunities for MediPharm Labs, Backed by the Company's Suite of Licenses and Proven U.S. Clinical Trial Supply Experience
From MediPharm Labs Corp.
Via GlobeNewswire
News headline image
MediPharm Labs Announces Board of Directors Changes: Shelley Potts Steps Down, Michael Bumby Returns
From MediPharm Labs Corp.
Via GlobeNewswire
News headline image
MediPharm Labs Completes First Shipment to France
From MediPharm Labs Corp.
Via GlobeNewswire
News headline image
MediPharm Announces Complete Dismissal of Defamation Action Initiated by Apollo, Nobul and Regan McGee Under Ontario Anti-SLAPP Law
From MediPharm Labs Corp.
Via GlobeNewswire
News headline image
MediPharm Advances Global Reach in Q3 2025 with Double-Digit Revenue Growth and Strong International Medical Cannabis Gains
From MediPharm Labs Corp.
Via GlobeNewswire
News headline image
MediPharm Labs Sets Date to Report Third Quarter 2025 Financial Results
From MediPharm Labs Corp.
Via GlobeNewswire
News headline image
MediPharm Strengthens Global Position in Q2 2025, with 14% Revenue Growth and 50% Increase in International Medical Cannabis
From MediPharm Labs Corp.
Via GlobeNewswire
News headline image
MediPharm Labs Sets Date to Report Second Quarter 2025 Financial Results
From MediPharm Labs Corp.
Via GlobeNewswire
News headline image
MediPharm Labs Expands Leading CBN Oil Portfolio with The Launch of New Nighttime Inhaler
From MediPharm Labs Corp.
Via GlobeNewswire
News headline image
MediPharm Announces Voting Results from the 2025 Annual and Special Meeting of Shareholders
From MediPharm Labs Corp.
Via GlobeNewswire
News headline image
MediPharm Cautions Shareholders To Await Final Results of Annual and Special Meeting
From MediPharm Labs Corp.
Via GlobeNewswire
News headline image
Apollo Capital Wins Proxy Contest at MediPharm Labs
From Apollo Technology Capital Corporation
Via GlobeNewswire
News headline image
Leading Independent Proxy Advisor Glass Lewis Recommends Shareholders Vote the GREEN proxy FOR ALL MediPharm Director Nominees
From MediPharm Labs Corp.
Via GlobeNewswire
News headline image
MediPharm Reminds Shareholders to Vote in Advance of June 13 Deadline
Shareholders Urged to Vote for Proven Strategy and Team, Reject Dissident’s Inadequate Plan and Nominees 
From MediPharm Labs Corp.
Via GlobeNewswire
News headline image
MediPharm Announces Complete Dismissal of Dissident Court Proceeding Related to Annual and Special Meeting
From MediPharm Labs Corp.
Via GlobeNewswire
News headline image
Apollo Capital Releases Investor Presentation Highlighting Plan to Make MediPharm Labs the World’s Leading International Medical Cannabis Company
From Apollo Technology Capital Corporation
Via GlobeNewswire
News headline image
This Week In Cannabis: America's Crackdown Down On Hemp, Global Reform, Industry Gathering In Chicago ↗
Congress advances hemp THC ban as cannabis leaders prep for Benzinga's Chicago conference. Global markets shift. Here's the full recap. 
Via Benzinga
Topics Cannabis
News headline image
MediPharm Labs Closes $4.5 Million Sale of Hope, BC Facility and Announces Plans to Expand EU GMP Cultivation Capacity at Napanee Facility
From MediPharm Labs Corp.
Via GlobeNewswire
< Previous 1 2 3 Next >